Table 2.
Cancer type | Study | No. of patients | Evaluation index | Drug use period | Drugs |
---|---|---|---|---|---|
Breast cancer | Spera et al. (83) | 1,144 | Progression-free survival, overall response rate, and clinical benefit | During chemotherapy | β-blockers |
Shaashua et al. (84) | 38 | Epithelial-to-mesenchymal transition Transcription factors (GATA-1, GATA-2, EGR3, STAT-3) Tumor-infiltrating monocytes; B cells |
Perioperative period | Propranolol Etodolac (COX2 inhibitor) | |
Haldar et al. (82) | 38 | Pro-inflammatory cytokines (IL-6, CRP, and IFN-γ) Transcription factors (NF-κB, STAT3, ISRE) Proliferation marker Ki-67 PBMCs transcriptome |
Perioperative period | Propranolol Etodolac | |
Lung cancer | Chaudhary et al. (81) | 77 | Pathological and imaging response, metastatic rate, and survival | During chemoradiotherapy | Propranolol |
Ovarian cancer | Ramondetta et al. (80) | 32 | Anxiety, and depression Leukocyte expression of pro-inflammatory genes Serum IL-6, IL-8, IL-10 |
Before starting chemotherapy or surgery | Propranolol |